Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.350-2.650 for the period, compared to the consensus earnings per share estimate of 2.540. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Teva Pharmaceutical Industries also updated its Q1 2025 guidance to 0.520-0.520 EPS.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $15.52 on Friday. The stock’s 50 day moving average price is $17.35 and its 200 day moving average price is $18.14. The stock has a market cap of $17.60 billion, a price-to-earnings ratio of -10.71, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research reports. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.